ATRN protein-targeted antibody or antigen-binding fragment thereof and application of ATRN protein-targeted antibody or antigen-binding fragment

By developing antibodies or antigen-binding fragments of ATRN protein that can bind ATRN protein with high specificity and affinity, the problem of lack of efficient antibodies against ATRN protein in the prior art has been solved, and effective regulation of ATRN protein is achieved, and it can treat obesity and neurological diseases are achieved. and potential applications of immunomodulation.

CN118909108AActive Publication Date: 2024-11-08UNIV OF SCI & TECH OF CHINA

Patent Information

Application Number
CN202411024067.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-08
Estimated Expiration
2044-07-26

AI Technical Summary

Technical Problem

The lack of high affinity and high specificity antibodies against ATRN proteins has limited its application in disease treatment.

Method used

Develop an antibody or antigen-binding fragment of its antigen-binding fragment containing the heavy chain complementary determining region HCDR, which can bind ATRN protein with high specificity and affinity, block its interaction with receptors, inhibit signal transduction, and thus regulate obesity in organisms. Melanin deposition, nerve cell function and anti-tumor function of immune cells.

Benefits of technology

It has achieved high specificity and affinity binding to ATRN protein, blocking its signal transduction, restoring cell activity, regulating related biological functions, and has potential treatment of obesity, neurological diseases and immune regulation functions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909108A_ABST
    Figure CN118909108A_ABST
Patent Text Reader

Abstract

The invention relates to an ATRN protein targeting antibody or an antigen binding fragment thereof and application thereof, and belongs to the field of antibodies. The antibody or the antigen binding fragment thereof comprises a heavy chain complementarity determining region HCDR, and the HCDR comprises at least one selected from SEQ ID NO: 1-3 or an amino acid sequence having at least 80% homology with the HCDR. The antibody or the antigen binding fragment thereof can bind to human ATRN protein with high specificity and affinity, block the interaction with a receptor, inhibit a signal transduction process and recover cell activity, so as to regulate the obesity of organisms, melanin deposition, nerve cell functions and anti-tumor functions of immune cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of antibodies, and specifically, relates to antibodies or antigen-binding fragments thereof of ATRN protein and applications thereof. Background Art

[0002] ATRN (Attractin) is a membrane-associated molecule that is rapidly upregulated on activated T cells, has CD26 protease activity, and is encoded by the ATRN gene on human chromosome 20. ATRN is expressed in a variety of tissues, including skin, brain, liver, and adipose tissue, indicating that it has important functions in a variety of physiological processes.

[0003] ATRN performs immunomodulatory functions by capturing and proteolytically modifying the N-termini of a variety of cytokines and chemokines. This regulatory activity allows immune cells to interact and form immunomodulatory clusters, and helps to downregulate chemokine and cytokine activity after initiating a response. In addition, ATRN also plays an important role in adipocyte differentiation, neural function, skin pigmentation, and extracellular matrix interactions. High expression of ATRN is associated with diseases related to metabolic disorders such as obesity, while in the nervous system, ATRN is involved in neuronal development, synaptic function, and neuroprotection, becoming a hot topic in the study of neurological diseases.

[0004] ATRN also interacts with a variety of proteins, including LRP1, Syndecans, HSPGs, Neogenin, and NCAM, and is involved in cell signaling, adhesion, and neural development. Therefore, blocking the interaction between ATRN and other proteins may have potential value in the treatment of related diseases. However, its specific mechanism of action and its role in disease states are still not fully understood, and there is a lack of specific antibodies against ATRN.

[0005] Therefore, it is urgent to develop a high-affinity therapeutic anti-ATRN antibody. Summary of the invention

[0006] The present application aims to solve at least one of the above technical problems. To this end, one object of the present application is to provide an antibody that binds to human ATRN protein with high affinity and high specificity.

[0007] Specifically, this application provides the following technical solutions:

[0008] In the first aspect of the present application, the present application proposes an antibody or an antigen-binding fragment thereof. According to an embodiment of the present application, it comprises: a heavy chain complementary determining region HCDR, wherein the HCDR comprises at least one selected from SEQ ID NO: 1 to 3 or an amino acid sequence having at least 80% homology thereto. In some examples of the present application, the aforementioned antibody or its antigen-binding fragment can bind to the ATRN extracellular segment protein with high specificity and affinity, and block its interaction with the receptor, inhibit the signal transduction process, and restore cell activity, thereby regulating the obesity, melanin deposition, nerve cell function, and anti-tumor function of immune cells of the organism.

[0009] It should be noted that the aforementioned term "receptor" includes melanocortin receptor, melanocortin / adrenocorticotropic hormone (ACTH) receptor, melanocortin receptor, melanocortin receptor, melanocortin receptor or other receptors that interact with ATRN. In some examples of the present application, the aforementioned other receptors that interact with ATRN have biological functions.

[0010] In the second aspect of the present application, the present application proposes a nucleic acid molecule. According to an embodiment of the present application, the nucleic acid molecule encodes the antibody or antigen-binding fragment thereof described in the first aspect of the present application. In some examples of the present application, based on the above nucleic acid molecule, the above antibody or antigen-binding fragment thereof can be efficiently expressed in vitro. Based on the nucleic acid molecule, the above antibody or antigen-binding fragment thereof can be expressed in large quantities in vitro.

[0011] In the third aspect of the present application, the present application proposes an expression vector. According to an embodiment of the present application, the expression vector carries the nucleic acid molecule described in the second aspect of the present application. In some examples of the present application, after the expression vector is introduced into a suitable recipient cell, the expression of the aforementioned antibody or its antigen-binding fragment can be effectively achieved under the mediation of a regulatory system, thereby achieving a large-scale in vitro preparation of the antibody or its antigen-binding fragment.

[0012] In the fourth aspect of the present application, the present application proposes a method for preparing the antibody or antigen-binding fragment thereof described in the first aspect. According to an embodiment of the present application, the method comprises: introducing the expression vector described in the third aspect of the present application into a cell; culturing the cell under conditions suitable for protein expression and secretion to obtain the antibody or antigen-binding fragment thereof. In some examples of the present application, based on the above method, antibodies or antigen-binding fragments thereof that can bind to ATRN protein with high specificity and affinity can be efficiently prepared in vitro.

[0013] In the fifth aspect of the present application, the present application proposes a recombinant cell. According to an embodiment of the present application, the recombinant cell carries the antibody or antigen-binding fragment thereof described in the first aspect of the present application, the nucleic acid molecule described in the second aspect, or the expression vector described in the third aspect. Wherein, the aforementioned recombinant cell is obtained by transfecting or transforming the expression vector. In some examples of the present application, the recombinant cell can efficiently express the above-mentioned antibody or antigen-binding fragment thereof under suitable conditions, and the obtained antibody or antigen-binding fragment thereof can bind to ATRN protein with high specificity and affinity.

[0014] In the sixth aspect of the present application, the present application proposes a recombinant protein. According to an embodiment of the present application, the recombinant protein includes: the antibody or antigen-binding fragment thereof described in the first aspect of the present application. In some examples of the present application, the aforementioned engineered protein can effectively target the ATRN protein, block its interaction with the receptor, inhibit the signal transduction process, and restore cell activity, thereby regulating the obesity, melanin deposition, nerve cell function, and anti-tumor function of immune cells in organisms.

[0015] In the seventh aspect of the present application, the present application proposes a composition. According to an embodiment of the present application, the composition includes: the antibody or antigen-binding fragment thereof described in the first aspect of the application, the nucleic acid molecule described in the second aspect, the expression vector described in the third aspect, the recombinant cell described in the fifth aspect, or the recombinant protein of the sixth aspect. As mentioned above, the antibody or its antigen-binding fragment can bind to the ATRN protein with high specificity and affinity. Therefore, a composition comprising the antibody or its antigen-binding fragment, such as a food composition, a pharmaceutical composition, etc., can also effectively target the ATRN protein, block its interaction with the receptor, inhibit the signal transduction process, and restore cell activity, thereby regulating obesity, melanin deposition, nerve cell function, and anti-tumor function of immune cells in organisms.

[0016] In the eighth aspect of the present application, the present application proposes the use of the antibody or antigen binding fragment thereof described in the first aspect, the nucleic acid molecule described in the second aspect, the expression vector described in the third aspect, the recombinant cell described in the fifth aspect, the recombinant protein described in the sixth aspect, or the composition described in the seventh aspect in the preparation of a drug, the drug is used to treat or prevent ATRN-mediated related diseases. In some examples of the present application, the drug prepared based on the antibody or antigen binding fragment thereof, recombinant protein, nucleic acid molecule, expression vector, recombinant cell or pharmaceutical composition, the aforementioned antibody or antigen binding fragment thereof can bind to the ATRN protein with high specificity and affinity, block its interaction with the receptor, inhibit the signal transduction process, and restore cell activity, thereby regulating obesity, melanin deposition, nerve cell function and anti-tumor function of immune cells in the organism.

[0017] In the ninth aspect of the present application, the present application proposes a drug. According to an embodiment of the present application, the drug includes: the antibody or antigen-binding fragment thereof described in the first aspect, the nucleic acid molecule described in the second aspect, the expression vector described in the third aspect, the recombinant cell described in the fifth aspect, the recombinant protein in the sixth aspect, or the composition described in the seventh aspect, and the drug is used to treat or prevent ATRN-mediated related diseases. In some examples of the present application, drugs prepared based on antibodies or antigen-binding fragments thereof, recombinant proteins, nucleic acid molecules, expression vectors, recombinant cells or pharmaceutical compositions can effectively target ATRN protein, block its interaction with receptors, inhibit signal transduction processes, and restore cell activity, thereby regulating obesity, melanin deposition, nerve cell function, and anti-tumor function of immune cells in organisms.

[0018] In the tenth aspect of the present application, the present application proposes the use of the antibody or antigen-binding fragment thereof described in the first aspect in preparing a kit for detecting ATRN. In some examples of the application, the kit prepared based on the antibody or antigen-binding fragment thereof, recombinant protein, nucleic acid molecule, expression vector or recombinant cell can be used for portable detection of ATRN protein.

[0019] In the eleventh aspect of the present application, the present application proposes a kit. According to an embodiment of the present application, the kit comprises the antibody or antigen-binding fragment thereof described in the first aspect. As previously mentioned, the antibody or antigen-binding fragment thereof can bind to the ATRN protein with high specificity and affinity. Therefore, the kit comprising the antibody or antigen-binding fragment thereof can be used for efficient and portable detection of ATRN. In some examples of the present application, the kit can be used for scientific research, such as qualitative or quantitative detection of ATRN protein in biological samples, and can also be used to judge the status of an individual, such as after obtaining the ATRN level of the individual, judging whether the ATRN level is higher or lower than the normal level.

[0020] Additional aspects and advantages of the present application will be given in part in the description below, and in part will become apparent from the description below, or will be learned through the practice of the present application. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0022] Figure 1 It is a schematic diagram of the chromatography results of the purified ATRN extracellular segment protein (antigen) provided in the examples of the present application;

[0023] Figure 2 This is a schematic diagram of the results of SDS-PAGE characterization of ATRN protein provided in the examples of the present application;

[0024] Figure 3 It is a schematic diagram of the antibody chromatography detection and purification results provided in the examples of the present application;

[0025] Figure 4 It is a schematic diagram of the chromatographic results of the enzymatic cleavage of the Nanobody to remove the FC segment and TEV protease provided in the Examples of the present application;

[0026] Figure 5 It is an electrophoresis diagram of the protein SDS-PAGE gel provided in the embodiment of the present application; wherein, Nb(UD) represents a nanobody containing an FC fragment; Nb(Dig) represents a nanobody after enzyme cleavage and separation by a nickel column and a Protein A column; FC represents an FC fragment separated from a nanobody after enzyme cleavage; TEV represents a tobacco etch virus protease separated from a nanobody after enzyme cleavage;

[0027] Figure 6 This is a schematic diagram of the results of Elisa detection of the binding ability of ATRN antigen and nanoantibody provided in the examples of the present application;

[0028] Figure 7 is a schematic diagram of the flow cytometry detection of the ability of nanobodies to stimulate human peripheral blood mononuclear cells (PBMCs) to secrete cytokines provided in the examples of the present application; wherein, ISO in Figure 7 (A) represents a sample of isotype control flow cytometry antibody detected by ATRN flow cytometry antibody after 96 hours of PHA stimulation, Ctrl represents a sample detected by ATRN flow cytometry antibody without PHA stimulation, PHA represents a sample detected by ATRN flow cytometry antibody after 96 hours of PHA stimulation, the vertical axis of the flow graph is the number of cells, and the horizontal axis is the fluorescence intensity of AF647; Figure 7 (B) represents the gate representation of the flow cytometry detection of NK cell cytokine secretion ability Figure 7 (C) shows the representative graph and statistical graph of the gate for flow cytometry detection of the ability of CD8+ T cells to secrete cytokines, FC is the control group of PBMC stimulated by FC protein, Anti-ATRN is the experimental group of PBMC stimulated by nanoantibodies, the vertical axis of the flow cytometer is the fluorescence intensity of the BV421 fluorescence channel, and the horizontal axis is the fluorescence intensity of the BV605 fluorescence channel; Figure 7 (C) shows the representative graph and statistical graph of the gate for flow cytometry detection of the ability of CD8+ T cells to secrete cytokines, FC is the control group of PBMC stimulated by FC protein, Anti-ATRN is the experimental group of PBMC stimulated by nanoantibodies, the vertical axis of the flow cytometer is the fluorescence intensity of the FITC, BV421, APC fluorescence channels, and the horizontal axis is the fluorescence intensity of the PC7 fluorescence channel;

[0029] Figure 8 This is a schematic diagram of the anti-ATRN nanoantibody provided in the examples of the present application inhibiting the growth of HepG2 subcutaneous tumors. DETAILED DESCRIPTION

[0030] The embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are exemplary and intended to be used to explain the present invention, and should not be understood as limiting the present application.

[0031] In the present application, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include at least one of the features. In the description of the present application, "plurality" means at least two, such as two, three, etc., unless otherwise clearly and specifically defined.

[0032] In this application, the term "antibody" refers to an immunoglobulin, which is composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds. The amino acid composition and arrangement order of the constant region of the immunoglobulin heavy chain are different, so their antigenicity is also different. Immunoglobulins can be divided into five categories, namely IgM, IgD, IgG, IgA, and IgE. The same class of immunoglobulins can also be divided into different subclasses based on the amino acid composition, such as IgG1, IgG2, IgG3, and IgG4. Immunoglobulin light chains are divided into kappa chains or lambda chains based on the different constant regions.

[0033] The sequences of about 110 amino acids near the N-terminus of the antibody heavy and light chains vary greatly, which is the variable region (Fv region); the remaining amino acid sequences near the C-terminus are relatively stable, which is the constant region. The variable region includes three hypervariable regions (HVRs) and four relatively conservative framework regions (FRs). The three hypervariable regions determine the specificity of the antibody, also known as the complementarity determining regions (CDRs). Each light chain variable region (LCVR) and heavy chain variable region (HCVR) consists of three CDR regions and four FR regions, arranged in the order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The three CDR regions of the light chain refer to LCDR1, LCDR2, and LCDR3; the three CDR regions of the heavy chain refer to HCDR1, HCDR2, and HCDR3.

[0034] In this application, the term "monoclonal antibody (abbreviated as MAb)" refers to an antibody that can only recognize one specific antigen epitope. Among them, common MAbs include two light chains with lighter molecular weight and two heavy chains with heavier molecular weight. The heavy chain (H chain) and the light chain (L chain) are connected by disulfide bonds to form a tetrapeptide chain molecule. The amino acid sequence of the amino terminal (N terminal) of the heavy chain or light chain varies greatly, which is called the variable region (V region). The carboxyl terminal (C terminal) of the heavy chain or light chain is relatively stable and varies little, which is called the constant region (C region); the V regions of the L chain and H chain are called VL and VH, respectively. MAbs can also be small molecule antibodies, which mainly include: Fab antibodies, Fv antibodies, single-chain antibodies, single-domain antibodies and minimum recognition units.

[0035] In the present application, the term "polyclonal antibody (abbreviated as polyantibody)" refers to an antibody that can recognize multiple antigenic epitopes, such as an antibody that can recognize two antigenic epitopes (abbreviated as double antibody), an antibody that can recognize three antigenic epitopes, or an antibody that can recognize four antigenic epitopes. It is understood in a broad sense and the specific structure is not limited as long as it can recognize multiple antigenic epitopes.

[0036] In the present application, the term "nanobody" comprises only the heavy chain variable region (VH) and conventional CH2 and CH3 regions, which specifically bind to the antigen via the heavy chain variable region.

[0037] In the present application, the term "antigen-binding fragment" refers to a Fab fragment, Fab' fragment, F(ab')2 fragment, Fv fragment or ScFv fragment with antigen-binding activity; it comprises one or more CDR regions of the antibody described in the present application selected from SEQ ID NOs: 1 to 3.

[0038] In the present application, the amino acid sequences of the CDRs listed above are all shown in accordance with the IMGT definition rules. However, it is well known to those skilled in the art that the CDRs of antibodies can be defined in the art by a variety of methods, such as the Kabat rule, the Chothia rule, etc. It should be understood by those skilled in the art that, unless otherwise specified, the terms "CDR" and "complementarity determining region" of a given antibody or a region thereof (such as a variable region) should be understood to cover the complementary determining region defined by any of the above-mentioned known schemes described in the present invention. Although the scope of protection requested in the present application is based on the sequences shown in the IMGT definition rules, the amino acid sequences corresponding to the definition rules of other CDRs should also be included in the scope of protection of the present application.

[0039] In the present application, the term "amino acid" is represented by a single-letter or three-letter code and has the following meaning: A: Ala (alanine); R: Arg (arginine); N: Asn (asparagine); D: Asp (aspartic acid); C: Cys (cysteine); Q: Gln (glutamine); E: Glu (glutamate); G: Gly (glycine); H: His (histidine); I: Ile (isoleucine); L: Leu (leucine); K: Lys (lysine); M: Met (methionine); F: Phe (phenylalanine); P: Pro (proline); S: Ser (serine); T: Thr (threonine); W: Trp (tryptophan); Y: Tyr (tyrosine); V: Val (valine).

[0040] With respect to nucleotides, the terms "homology", "identity" or "similarity" are used to describe or compare the degree of nucleotide similarity of two or more nucleotide sequences. The percentage of "sequence homology" between a first sequence and a second sequence can be calculated by dividing [the number of nucleotides in the first sequence that are identical to the nucleotides at corresponding positions in the second sequence] minus [the total number of nucleotides in the first sequence] and then multiplying by [100%], where each deletion, insertion, substitution or addition of a nucleotide in the second nucleotide sequence - relative to the first nucleotide sequence - is considered to be a difference at a single nucleotide (position). Alternatively, the degree of sequence identity between two or more nucleotide sequences can be calculated using known computer algorithms for sequence alignment, such as NCBI Blast v2.0, using standard settings. Some other techniques, computer algorithms and arrangements for determining the degree of sequence identity are described, for example, in WO 04 / 037999, EP 0 967 284, EP 1 085089, WO 00 / 55318, WO 00 / 78972, WO 98 / 49185 and GB 2357768-A.

[0041] For polypeptides, the terms "(substantial) homology", "identity" or "similarity" are used to describe or compare the degree of amino acid similarity between two or more polypeptides or their designated sequences when optimally aligned and compared (where nucleotides are appropriately inserted or deleted). The % homology between two sequences varies with the number of identical positions shared by these sequences when the sequences are optimally aligned (i.e., % homology = number of identical positions / total number of positions × 100), wherein the optimal alignment is determined by taking into account the number of gaps that need to be introduced to achieve optimal alignment of the two sequences and the length of each gap. Sequence comparison and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.

[0042] In the present application, under the premise of not substantially affecting the activity of the antibody (retaining at least 95% of the activity), those skilled in the art may replace, add and / or delete one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more) amino acids in the sequence of the present application to obtain a variant of the sequence of the antibody or its functional fragment. They are all considered to be included in the scope of protection of the present invention. For example, amino acids with similar properties are replaced in the variable region. The variant sequence described in the present application may have at least 80% identity (or homology) with the reference sequence, which means at least 80% with each reference sequence, which may be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% identity. The sequence consistency described in the present application can be measured using sequence analysis software. For example, the computer program BLAST, especially BLASTP or TBLASTN, with default parameters is used. The amino acid sequences described in the present invention are all shown in the manner of N-terminus to C-terminus.

[0043] In this article, the term "vector" generally refers to a nucleic acid molecule that can be inserted into a suitable host and replicates itself, and the inserted nucleic acid molecule is transferred into and / or between host cells. The vector may include a vector that is mainly used to insert DNA or RNA into a cell, a vector that is mainly used to replicate DNA or RNA, and a vector that is mainly used for the expression of transcription and / or translation of DNA or RNA. The vector also includes a vector with a variety of the above functions. The vector can be a polynucleotide that can be transcribed and translated into a polypeptide when introduced into a suitable host cell. Typically, the vector can produce a desired expression product by cultivating a suitable host cell that contains the vector.

[0044] In this application, the term "composition" generally refers to a unit dosage form and can be prepared by any of the methods well known in the pharmaceutical art. All methods include the step of combining the active ingredient with a carrier that constitutes one or more accessory ingredients. Generally, the composition is prepared by uniformly and sufficiently combining the active compound with a liquid carrier, a finely divided solid carrier, or both.

[0045] In the present application, the term "pharmaceutically acceptable" ingredients are substances that are suitable for use in humans and / or mammals without excessive adverse side effects (such as toxicity, irritation and allergic response), ie, substances with a reasonable benefit / risk ratio.

[0046] In the present application, the term "pharmaceutically acceptable excipient" may include any solvent, solid excipient, diluent or other liquid excipient, etc., suitable for a specific target dosage form. Except for any conventional excipients incompatible with the compound of the present invention, such as any adverse biological effect produced or interaction with any other component of the pharmaceutically acceptable composition in a harmful manner, their use is also within the scope of the present invention.

[0047] In the present application, the term "administration" refers to introducing a predetermined amount of material into a patient by a suitable method. The antibody or antigen binding fragment, recombinant protein, multispecific antibody, conjugate or pharmaceutical composition of the present invention can be administered by any common route as long as it can reach the expected tissue. Various modes of administration are expected, including peritoneal, intravenous, intramuscular, subcutaneous injection, etc., but the present invention is not limited to these exemplified modes of administration. Preferably, the composition of the present invention is administered by intravenous or subcutaneous injection.

[0048] In the present application, the term "treatment" is used to refer to obtaining a desired pharmacological and / or physiological effect. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or may be therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, especially humans, including: (a) preventing the occurrence of a disease or condition in an individual who is susceptible to the disease but has not yet been diagnosed with the disease; (b) inhibiting the disease, such as blocking the progression of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a drug or compound to an individual to treat, cure, alleviate, improve, reduce or inhibit an individual's disease, including but not limited to administering a drug containing a compound described herein to an individual in need.

[0049] In the present application, the term "effective amount" or "effective dose" refers to an amount that can produce a function or activity on humans and / or animals and can be accepted by humans and / or animals.

[0050] In the present application, the amino acid sequences involved are shown in Table 1.

[0051] The present application proposes an antibody or an antigen-binding fragment thereof targeting ATRN protein, and a preparation method thereof, a nucleic acid molecule, an expression vector, a recombinant cell, a recombinant protein, a composition, pharmaceutical uses, a drug, uses in preparing a kit, a kit, a disease treatment method, and uses for disease treatment, which will be described in detail below.

[0052] Antibodies or antigen-binding fragments thereof

[0053] In one aspect of the present application, the present application proposes an antibody or an antigen-binding fragment thereof, comprising: a heavy chain complementary determining region HCDR, wherein the HCDR comprises at least one selected from SEQ ID NO: 1 to 3 or an amino acid sequence having at least 80% homology thereto. In some examples of the present application, the antibody or antigen-binding fragment thereof having the aforementioned HCDR amino acid sequence can bind to the ATRN protein with high affinity and specificity.

[0054] In some examples of the present application, the aforementioned HCDR includes: HCDR1, HCDR2 and HCDR3, wherein the aforementioned HCDR1 comprises an amino acid sequence as shown in SEQ ID NO: 1 or having at least 80% homology to SEQ ID NO: 1, the aforementioned HCDR2 comprises an amino acid sequence as shown in SEQ ID NO: 2 or having at least 80% homology to SEQ ID NO: 2, and the aforementioned HCDR3 comprises an amino acid sequence as shown in SEQ ID NO: 3 or having at least 80% homology to SEQ ID NO: 3. Antibodies or antigen-binding fragments thereof based on the aforementioned HCDR sequences have high binding affinity and specificity to the ATRN protein.

[0055] In some preferred examples of the present application, the aforementioned HCDR includes: HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NOs: 1 to 3. Experimental verification shows that antibodies or antigen-binding fragments thereof having amino acid sequences as shown in SEQ ID NOs: 1 to 3 have high binding affinity and specificity to ATRN protein.

[0056] In some examples of the present application, the aforementioned antibody or antigen-binding fragment thereof further includes: a light chain complementary determining region LCDR, and the aforementioned LCDR includes: LCDR1, LCDR2 and LCDR3.

[0057] It should be noted that one or more amino acid residues in the aforementioned HCDR targeting ATRN protein can be replaced by other amino acid residues from the same side chain family, and the retained function of the altered antibody can be tested using the functional assay method described herein.

[0058] In some examples of the present application, the aforementioned antibody or antigen-binding fragment thereof further includes: a heavy chain framework region.

[0059] In some examples of the present application, at least a portion of the aforementioned heavy chain framework region is independently derived from at least one of an alpaca antibody, a shark antibody, a mouse antibody, a rabbit antibody, a primate antibody, or a mutant thereof. In a preferred example of the present application, the aforementioned heavy chain framework region is selected from an alpaca antibody.

[0060] In some preferred examples of the present application, the heavy chain variable region of the aforementioned antibody or antigen-binding fragment thereof comprises an amino acid sequence selected from SEQ ID NO: 4 or having at least 80% homology with SEQ ID NO: 4. In some more preferred examples of the present application, the amino acid sequence of the heavy chain variable region of the aforementioned antibody or antigen-binding fragment thereof is as shown in SEQ ID NO: 4.

[0061] In some examples of the present application, the aforementioned antibody or antigen-binding fragment thereof further includes: a light chain framework region.

[0062] In some examples of the present application, at least a portion of the light chain framework region is independently derived from at least one of a murine antibody, a rabbit antibody, a primate antibody, or a mutant thereof.

[0063] The antibody or antigen-binding fragment thereof based on the above heavy chain variable region sequence has high binding affinity and specificity to the ATRN protein.

[0064] In some examples of the present application, the aforementioned antibody or antigen-binding fragment thereof further includes: a heavy chain constant region.

[0065] In some examples of the present application, the aforementioned antibody or antigen-binding fragment thereof further includes: a light chain constant region.

[0066] In some examples of the present application, at least a portion of the aforementioned heavy chain constant region and the aforementioned light chain constant region are independently derived from at least one of a rabbit antibody, a mouse antibody, a sheep antibody, a goat antibody, a primate antibody, or a mutant thereof. In some preferred examples of the present application, at least a portion of the aforementioned heavy chain constant region and the aforementioned light chain constant region are derived from a mouse antibody.

[0067] In some examples of the present application, the aforementioned antibody includes at least one selected from a polyclonal antibody and a monoclonal antibody; or the aforementioned antigen-binding fragment includes at least one selected from a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, a scFv fragment, a scFv-Fv fusion protein and a minimum recognition unit.

[0068] In some preferred examples of the present application, the aforementioned antibody is a nanobody. The nanobody was first obtained by the inventors through AI model (HIE BL, SHANKER VR, XU D, et al. Efficient evolution of human antibodies from general protein language models [J]. Nature Biotechnology, 2024, 42 (2): 275-283.) to mutate the ATRN nano sequence, and showed excellent tumor inhibition effect in the HepG2 humanized tumor model.

[0069] Those skilled in the art will appreciate that the aforementioned antibodies or antigen-binding fragments are applicable to a variety of animal tumor models, including but not limited to mouse tumor models.

[0070] In some examples of the present application, the aforementioned nanobody has an amino acid sequence as shown in SEQ ID NO: 4 or having at least 80% homology with SEQ ID NO: 4. In some examples of the present application, after sufficient experimental verification, it was found that the nanobody having the amino acid sequence as shown in SEQ ID NO: 4 can bind to the ATRN protein with high affinity and high specificity.

[0071] According to the embodiments of the present application, the aforementioned antibodies or antigen-binding fragments can bind to the extracellular segment of the human ATRN protein, block the inhibitory signal transmission of ATRN on NK cells and CD8+T, promote the secretion of perforin by NK cells in human peripheral blood, and the ability of CD8+T cells to secrete interferon, tumor necrosis factor, and perforin, thereby enhancing the killing function of NK cells and CD8+T cells.

[0072] Nucleic acid molecules

[0073] In another aspect of the present application, the present application proposes a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof as described above. In some examples of the present application, the antibody or antigen-binding fragment thereof can be efficiently expressed in vitro based on the aforementioned nucleic acid molecule.

[0074] In some examples of the present application, the nucleic acid molecule is DNA.

[0075] It should be noted that, for the nucleic acid molecules mentioned in the specification and claims of this application, those skilled in the art should understand that they actually include any one or both of the complementary double strands. For convenience, in this specification and claims, although only one strand is given in most cases, the other strand complementary thereto is actually disclosed. In addition, the nucleic acid sequence in this application includes DNA form or RNA form, and disclosing one of them means that the other is also disclosed.

[0076] Expression vector

[0077] In another aspect of the present application, the present application proposes an expression vector, wherein the expression vector carries the nucleic acid molecule as described above. In some examples of the present application, the antibody or antigen-binding fragment can be efficiently prepared in vitro based on the aforementioned expression vector.

[0078] It should be noted that when the above nucleic acid molecule is connected to a vector, the nucleic acid molecule and the control element on the vector can be directly or indirectly connected, as long as these control elements can control the translation and expression of the nucleic acid molecule. Of course, these control elements can come directly from the vector itself, or they can be exogenous, that is, not from the vector itself. Of course, the nucleic acid molecule and the control element can be operably connected.

[0079] According to an embodiment of the present invention, the vector may refer to a cloning vector or an expression vector, which can be obtained by operably connecting the nucleic acid to a commercially available vector (such as a plasmid or a viral vector). The vector in the present invention is not particularly limited, and commonly used plasmids can be used, such as pSeTag2, PEE14, pMH3, etc.

[0080] In this article, the term "operably linked" refers to connecting the exogenous gene to the vector so that the control elements in the vector, such as the amino acid sequence of transcription control such as and the amino acid sequence of translation control such as, can play their expected functions of regulating the transcription and translation of the exogenous gene. Commonly used vectors can be, for example, viral vectors, plasmids, phages, etc. After the expression vectors according to some specific embodiments of the present invention are introduced into suitable recipient cells, the expression of the nucleic acid molecules described above can be effectively achieved under the mediation of the regulatory system, thereby achieving the in vitro acquisition of a large amount of protein encoded by the nucleic acid molecules.

[0081] In some examples of the present application, the vector is a eukaryotic vector or a prokaryotic vector.

[0082] In some examples of the present application, the vector includes at least one selected from a plasmid vector, an adenovirus vector, a lentivirus vector, and an adeno-associated virus vector.

[0083] Method for preparing antibody or antigen-binding fragment thereof

[0084] In another aspect of the present application, the present application proposes a method for preparing the aforementioned antibody or its antigen-binding fragment, comprising: introducing the aforementioned expression vector into cells; culturing the cells under conditions suitable for protein expression and secretion, so as to obtain the aforementioned antibody or its antigen-binding fragment.

[0085] In some examples of the present application, the cell is a eukaryotic cell.

[0086] In some specific examples of the present application, the eukaryotic cell is a mammalian cell. When the cell is a mammalian cell, the expression efficiency of the antibody or antigen-binding fragment thereof is higher.

[0087] It should be noted that the eukaryotic cells do not include animal germ cells, fertilized eggs or embryonic stem cells.

[0088] Recombinant cells

[0089] In another aspect of the present application, the present application proposes a recombinant cell carrying the aforementioned antibody or antigen-binding fragment thereof, the aforementioned nucleic acid molecule or the aforementioned expression vector. In some examples of the present application, the recombinant cell is obtained by transfecting or transforming the expression vector, and the aforementioned recombinant cell can efficiently express the aforementioned antibody or antigen-binding fragment under appropriate conditions.

[0090] It should be noted that the recombinant cells described in the present application are not particularly limited and can be prokaryotic cells, eukaryotic cells or bacteriophages. The prokaryotic cells can be Escherichia coli, Bacillus subtilis, Streptomyces or Proteus mirabilis, etc. The eukaryotic cells can be fungi including Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces, Trichoderma, insect cells such as armyworms, plant cells such as tobacco, mammalian cells such as BHK cells, CHO cells, COS cells, myeloma cells, etc. In certain embodiments, the recombinant cells described in the present application are preferably mammalian cells, including BHK cells, CHO cells, NSO cells or COS cells, and do not include animal germ cells, fertilized eggs or embryonic stem cells.

[0091] The aforementioned "transformation" or "transfection" refers to the introduction of nucleic acid (e.g., vector) into cells by various techniques known in the art. Suitable host cells can be transformed or transfected with the DNA sequence of the present application, and can be used for the expression and / or secretion of the target protein. Suitable host cells can be transformed or transfected with the DNA sequence of the present invention, and can be used for the expression and / or secretion of the target protein. Examples of suitable host cells that can be used for the present invention include immortalized hybridoma cells, NS / 0 myeloma cells, 293 cells, Chinese hamster ovary (CHO) cells, HeLa cells, Cap cells (cells derived from human amniotic fluid), and CoS cells.

[0092] It should be noted that the "suitable conditions" described in the specification of this application refer to conditions suitable for the expression of antibodies in this application. It is easy for those skilled in the art to understand that conditions suitable for antibody expression include, but are not limited to, suitable transformation or transfection methods, suitable transformation or transfection conditions, healthy host cell states, suitable host cell density, suitable cell culture environment, and suitable cell culture time. "Suitable conditions" are not particularly limited, and those skilled in the art can optimize the conditions for optimal antibody expression according to the specific environment of the laboratory.

[0093] Recombinant protein

[0094] In another aspect of the present application, the present application proposes a recombinant protein, comprising: the aforementioned antibody or antigen-binding fragment thereof. In some examples of the present application, the recombinant protein can bind to ATRN protein with high affinity and high specificity.

[0095] In some examples of the present application, the aforementioned recombinant protein may further include at least one selected from a biologically active protein or a fragment thereof, a biologically active polypeptide or a fragment thereof.

[0096] In some examples of the present application, the biologically active protein or fragment thereof includes at least one selected from a protein tag, a protein toxin or a fragment thereof, a tumor necrosis factor or a fragment thereof, an interferon or a fragment thereof, a biological response regulator or a fragment thereof, and an Fc fragment.

[0097] The so-called "protein tag" generally refers to a polypeptide or protein fused with the target protein (antibody or antigen-binding fragment), which can be used for the expression, detection, disappearance or purification of the target protein, etc., including but not limited to His tag (also known as His-Tag, sequence HHHHHH), Flag tag (also known as Flag-Tag, sequence DYKDDDDK), GST tag (also known as GST-Tag, glutathione S-transferase tag), SUMO tag and C-Myc tag, etc.

[0098] The so-called "toxin" generally refers to a substance that is toxic to the host, including protein toxins and non-protein toxins. Among them, protein toxins include but are not limited to abrin, ricin A, Pseudomonas exotoxin and diphtheria toxin. In the present application, the protein toxin is preferably a protein toxin with enzymatic activity.

[0099] The so-called "tumor necrosis factor" generally refers to a substance that can cause hemorrhagic necrosis of various tumors, including but not limited to TNF-α and TNF-β.

[0100] The so-called "interferon" generally refers to a glycoprotein that has the ability to directly kill or inhibit viruses, including but not limited to IFN-α, INF-β and IFN-γ.

[0101] The so-called "biological response modifiers" generally refer to a class of protein substances that directly or indirectly enhance the body's anti-tumor effect through the immune system, including but not limited to lymphokines, IL-2, IL-6, IL-10 and GM-CSF.

[0102] The so-called "Fc fragment" generally refers to the Fc region from IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM, including CH2, CH3 region and optionally hinge region. Preferably, IgG, IgA1, IgA2, IgD, IgE or IgM is derived from alpaca, mouse or primate.

[0103] Composition

[0104] In another aspect of the present application, the present application proposes a composition, including: the aforementioned antibody or antigen-binding fragment thereof, the aforementioned nucleic acid molecule, the aforementioned expression vector, the aforementioned recombinant cell or the aforementioned recombinant protein. In some examples of the present application, the aforementioned composition can be used to prepare related products targeting ATRN protein, such as drugs, kits, etc.

[0105] It should be noted that the composition includes combinations separated in time and / or space, as long as they can work together to achieve the purpose of the present application. For example, the components contained in the composition can be administered to the subject as a whole, or separately. When the components contained in the composition are administered to the subject separately, each component can be administered to the subject simultaneously or sequentially.

[0106] Pharmaceutical use

[0107] In another aspect of the present application, the present application proposes the use of the aforementioned antibody or its antigen-binding fragment, the aforementioned nucleic acid molecule, the aforementioned expression vector, the aforementioned recombinant cell, the aforementioned recombinant protein or the aforementioned composition in the preparation of a drug, which is used to treat or prevent ATRN-mediated related diseases.

[0108] In some examples of the present application, the ATRN-mediated related diseases include neurological diseases, autism spectrum disorder (ASD), Alzheimer's disease, schizophrenia, Parkinson's disease, bipolar disorder, epilepsy, diabetic nephropathy, glomerulonephritis, chronic kidney disease, polycystic kidney disease, nephrotic syndrome, renal cell carcinoma, obesity, type 2 diabetes, non-alcoholic fatty liver disease, metabolic syndrome, hypothyroidism, Cushing's syndrome, hyperlipidemia, coronary artery disease, heart failure, stroke, peripheral artery disease, atrial fibrillation, atherosclerosis, hypertension, coronary artery disease, heart failure, arrhythmia, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, melanoma, breast cancer, lung cancer, colorectal cancer, prostate cancer, ovarian cancer, renal cell carcinoma, liver cancer, lung cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, thyroid cancer, skin cancer, prostate cancer, kidney cancer, endometrial cancer, cervical cancer and blood tumors.

[0109] drug

[0110] In another aspect of the present application, the present application proposes a drug, comprising: the aforementioned antibody or its antigen-binding fragment, the aforementioned nucleic acid molecule, the aforementioned expression vector, the aforementioned recombinant cell, the aforementioned recombinant protein or the aforementioned composition, wherein the drug is used to treat or prevent ATRN-mediated related diseases.

[0111] The ATRN-mediated related diseases include neurological diseases, autism spectrum disorder (ASD), Alzheimer's disease, schizophrenia, Parkinson's disease, bipolar disorder, epilepsy, diabetic nephropathy, glomerulonephritis, chronic kidney disease, polycystic kidney disease, nephrotic syndrome, renal cell carcinoma, obesity, type II diabetes, non-alcoholic fatty liver disease, metabolic syndrome, hypothyroidism, Cushing's syndrome, hyperlipidemia, coronary artery disease, heart failure, stroke, peripheral artery disease, atrial fibrillation, atherosclerosis, hypertension, coronary artery disease, heart failure, arrhythmia, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, melanoma, breast cancer, lung cancer, colorectal cancer, prostate cancer, ovarian cancer, renal cell carcinoma, liver cancer, lung cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, thyroid cancer, skin cancer, prostate cancer, kidney cancer, endometrial cancer, cervical cancer and blood tumors.

[0112] In some examples of the present application, a pharmaceutically acceptable excipient is further included.

[0113] In some examples of the present application, the auxiliary material includes: one or more pharmaceutically acceptable excipients, diluents, stabilizers or carriers.

[0114] In some examples of the present application, the pharmaceutical composition is an injection.

[0115] It should be noted that the pharmaceutical composition includes combinations separated in time and / or space, as long as they can work together to achieve the purpose of the present invention. For example, the components contained in the pharmaceutical composition can be administered to the subject as a whole, or separately. When the components contained in the pharmaceutical composition are administered to the subject separately, each component can be administered to the subject simultaneously or sequentially.

[0116] The drug of the present application contains a safe and effective amount of the active ingredient (antibody) of the present application and a pharmaceutically acceptable adjuvant. Such adjuvants include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. Usually, the drug preparation should match the mode of administration. The dosage form of the drug of the present application is injection, oral preparation (tablet, capsule, oral liquid), transdermal agent, sustained release agent. For example, it is prepared by conventional methods using physiological saline or an aqueous solution containing glucose and other adjuvants. The drug is preferably manufactured under sterile conditions.

[0117] The effective amount of the active ingredient described in the present application may vary depending on the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The aforementioned factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated by the patient, the patient's weight, the patient's immune status, the route of administration, etc. For example, depending on the urgency of the treatment situation, several divided doses may be administered daily, or the dose may be reduced proportionally.

[0118] The pharmaceutically acceptable excipients described in the present application include (but are not limited to): water, saline, liposomes, lipids, proteins, protein-antibody conjugates, peptide substances, cellulose, nanogels, or combinations thereof. The choice of carrier should match the mode of administration, which are well known to those of ordinary skill in the art.

[0119] Use in the preparation of kits

[0120] In yet another aspect of the present application, the present application proposes the use of the aforementioned antibody or antigen-binding fragment thereof in preparing a kit for detecting ATRN.

[0121] As mentioned above, the antibodies or antigen-binding fragments thereof of the embodiments of the present application can specifically bind to ATRN, and therefore, the antibodies or antigen-binding fragments thereof can be used to detect ATRN protein. Furthermore, it can be used to prepare ATRN-related kits and used in scientific research, such as qualitatively or quantitatively detecting ATRN protein molecules in biological samples. More specifically, it can be used for immunoblotting, immunoprecipitation, and other kits that involve detection using the specific binding properties of ATRN and antibodies. These kits may contain any one or more of the following: antagonists, antibodies or drug reference materials of the present application; protein purification columns; immunoglobulin affinity purification buffers; cell assay diluents. The antibodies of the present application can be used for different types of diagnostic tests, for example, various diseases or the presence of drugs, toxins or other proteins can be detected in vitro or in vivo. For example, the serum or blood of the subject can be tested to test ATRN-mediated related diseases (such as liver cancer, etc.).

[0122] Reagent test kit

[0123] In another aspect of the present application, the present application proposes a kit comprising the antibody or antigen-binding fragment thereof described in the first aspect. The antibody or antigen-binding fragment thereof in the kit provided by the present application can effectively bind to the ATRN protein. In addition, under suitable conditions, the nucleic acid molecule, expression vector or recombinant cell can express the antibody or antigen-binding fragment thereof. Further, the kit comprising the above substances can bind to ATRN with high specificity and can be used to effectively detect ATRN. The kit can be used for scientific research, such as qualitative or quantitative detection of ATRN in biological samples, and can also be used to judge the status of an individual, such as after obtaining the ATRN level of the individual, judging whether the ATRN level is too high or lower than the normal level. The biological sample can be a cell, tissue, etc.

[0124] In some examples of the present application, the kit is used to detect ATRN.

[0125] Disease treatment methods

[0126] In another aspect of the present application, the present application provides a method for preventing and / or treating ATRN-mediated diseases. According to an embodiment of the present application, the method comprises: administering to a subject a pharmaceutically acceptable amount of an antibody or an antigen-binding fragment thereof, an expression vector, a recombinant cell, a recombinant protein, a composition or a drug.

[0127] It should be noted that the terms "subject", "individual" and "patient" are used interchangeably herein and refer to a mammal that is evaluated for treatment and / or treated. In one embodiment, the mammal is a human. The terms "subject", "individual" and "patient" include, but are not limited to, individuals with cancer, individuals with autoimmune diseases, individuals with pathogen infection, etc. The subject can be a human, but also includes other mammals, particularly mammals that can be used as laboratory models of human diseases, such as mice, rats, etc.

[0128] The effective amount of the antibody or antigen-binding fragment thereof, nucleic acid molecule, expression vector, recombinant protein, composition or drug described in the present application may vary depending on the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated for the patient, the patient's weight, the patient's immune status, the route of administration, etc. For example, depending on the urgency of the treatment situation, several divided doses may be administered daily, or the dose may be reduced proportionally.

[0129] In some examples of the present application, the ATRN-mediated related diseases include neurological diseases, autism spectrum disorder (ASD), Alzheimer's disease, schizophrenia, Parkinson's disease, bipolar disorder, epilepsy, diabetic nephropathy, glomerulonephritis, chronic kidney disease, polycystic kidney disease, nephrotic syndrome, renal cell carcinoma, obesity, type II diabetes, non-alcoholic fatty liver disease, metabolic syndrome, hypothyroidism, Cushing's syndrome, hyperlipidemia, coronary artery disease, heart failure, stroke, peripheral artery disease, atrial fibrillation, atherosclerosis, hypertension, coronary artery disease, heart failure, arrhythmia, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, melanoma, breast cancer, lung cancer, colorectal cancer, prostate cancer, ovarian cancer, renal cell carcinoma, liver cancer, lung cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, thyroid cancer, skin cancer, prostate cancer, kidney cancer, endometrial cancer, cervical cancer and blood tumors.

[0130] Disease treatment uses

[0131] In another aspect of the present application, the present application proposes the use of the aforementioned antibodies or antigen-binding fragments thereof, nucleic acid molecules, expression vectors, recombinant proteins, compositions or drugs in treating or preventing ATRN-mediated related diseases. In some examples of the present application, administering an effective dose of an antibody or antigen-binding fragment thereof, nucleic acid molecules, expression vectors, recombinant proteins, compositions or drugs to a subject can effectively treat ATRN-mediated diseases.

[0132] In some examples of the present application, the ATRN-mediated related diseases include neurological diseases, autism spectrum disorder (ASD), Alzheimer's disease, schizophrenia, Parkinson's disease, bipolar disorder, epilepsy, diabetic nephropathy, glomerulonephritis, chronic kidney disease, polycystic kidney disease, nephrotic syndrome, renal cell carcinoma, obesity, type II diabetes, non-alcoholic fatty liver disease, metabolic syndrome, hypothyroidism, Cushing's syndrome, hyperlipidemia, coronary artery disease, heart failure, stroke, peripheral artery disease, atrial fibrillation, atherosclerosis, hypertension, coronary artery disease, heart failure, arrhythmia, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, melanoma, breast cancer, lung cancer, colorectal cancer, prostate cancer, ovarian cancer, renal cell carcinoma, liver cancer, lung cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, thyroid cancer, skin cancer, prostate cancer, kidney cancer, endometrial cancer, cervical cancer and blood tumors.

[0133] Table 1

[0134]

[0135] The scheme of the present application will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present application and should not be considered as limiting the scope of the present application. If no specific technology or conditions are indicated in the embodiments, the technology or conditions described in the literature in this area or the product specification are carried out. The reagents used or the instruments that do not indicate the manufacturer are all conventional products that can be obtained commercially.

[0136] Example 1: Expression, purification and elution of ATRN extracellular segment protein

[0137] In this example, the specific steps of expressing, purifying and eluting the ATRN extracellular segment protein are as follows:

[0138] Primers were designed to amplify the ATRN extracellular segment gene fragment using the full-length ATRN gene sequence as a template, and the vector was selected from pTT5. Gibson assembly was used to construct the pTT5-ATRN plasmid.

[0139] The extracted plasmid was transfected into HEK293F cells using the transfection reagent polyethyleneimine (PEI). The reagents and amounts used are shown in Table 2. The pTT5-ATRN plasmid was used to transfect the mammalian expression system.

[0140] Table 2 Reagents and dosages of transfection system

[0141]

[0142]

[0143] DMEM was preheated in a 37°C water bath before transfection. Two 50ml tubes were filled with 15ml DMEM, and then the plasmid was added to one of the tubes and PEI was added to the other tube. The two tubes were left standing at room temperature for 10 minutes. The PEI diluted with DMEM was then transferred to the plasmid tube and incubated at room temperature for 15 minutes. HEK293F cells were grown at a count of 2 million / ml and a total volume of 350ml. After the plasmid-PEI incubation, it was transferred dropwise to 400ml cells and then left standing in a 37°C incubator for 20 minutes without shaking. Subsequently, the cells were cultured in a shaking incubator at 120rpm, 5% CO2 for 72 to 96 hours. The cells were centrifuged at 4347rcf for 30 minutes, and the supernatant was then passed through 0.45μm and 0.22μm filters, respectively. The filtered sample was loaded onto a peristaltic pump and the protein was purified using affinity chromatography (protein A column). The pTT5 vector carries an Fc (IgG) tag, which can specifically bind to the resin of the Protein A column, thereby enriching the target protein in the supernatant onto the column.

[0144] After loading, the protein column was eluted on the AKTA prime plus purification system, 0.2M Tris-HCl (pH=7) was added to the protein collection tube, and the program was run to elute the protein from 0% B elution buffer to 100% B solution. Liquid A used was PBS, and liquid B was elution buffer (0.1M acetic acid solution) to elute the bound protein. The harvested protein peak is shown in Figure 1 As shown, it is shown that high-purity ATRN extracellular segment protein is obtained.

[0145] Example 2: Detection of ATRN extracellular segment protein

[0146] The ATRN extracellular segment protein sample obtained in Example 1 was added to the stain and denatured at 95 degrees Celsius for 3 minutes to denature the protein. A 12.5% ​​SDS-gel electrophoresis gel was prepared using the supplier (Omni-Easy One-Step SDS-Gel Pretreatment Kit) according to the standard instructions, and transferred to an electrophoresis tank filled with running buffer (Tris-glycine buffer), and the samples and standard markers were loaded into the corresponding wells. The power was turned on, and the voltage was set to 90 volts for 20 minutes, and then increased to 130 volts until the dye reached the bottom. The gel was stained with a cresyl blue solution to visualize the protein bands, and the gel was placed in a staining solution for appropriate staining. The gel was rinsed with water and incubated at 70 degrees Celsius (the water was changed after 10 minutes until the background became clear and then the protein bands became visible) to remove excess dye from the gel. The gel was imaged using a gel imaging system, such as Figure 2 As shown, it is shown that the ATRN extracellular segment protein of the correct size is obtained.

[0147] Example 3: Mutation and purification and elution of anti-ATRN nanobodies

[0148] The existing ATRN nanoantibody sequence was analyzed by the AI ​​model (HIE BL, SHANKER VR, XU D, et al. Efficient evolution of human antibodies from general protein language models [J]. Nature Biotechnology, 2024, 42 (2): 275-283.), and relevant amino acid mutations were performed. The corresponding nucleotide sequence was synthesized by the company and cloned into the pTT5 vector, and purified using the method in Example 1.

[0149] Antibody chromatography test results Figure 3 As shown, it was shown that high-purity antibodies were obtained.

[0150] Example 4: TEV cleavage of anti-ATRN nanobody with FC segment

[0151] In order to detect the binding ability of specific nanobodies to ATRN antigens with FC using ELISA, the FC segment of the nanobody was further enzymatically cleaved and the VHH segment of the anti-ATRN antibody was purified. To this end, the purified nanobody was cleaved by tobacco etch virus protease (Tobacco Etch Virus protease, also known as TEV protease). TEV protease was added to the collected protein and stored at 4°C overnight. Subsequently, the digested protein was passed through a protein column (ProteinA) and a nickel (Ni-NTA) column to completely remove undigested protein, FC, and TEV enzyme, respectively.

[0152] The protein A and nickel column were then eluted to verify successful removal of the FC tag and TEV protease. Figure 4 As shown, the FC tag and TEV protease were successfully removed from the mixture.

[0153] The undigested nanobody protein, the FC fragment-removed nanobody protein after digestion, the FC fragment, and TEV protease were subjected to SDS-PAGE electrophoresis. The results are as follows: Figure 5 As shown, it shows that the sizes of the proteins obtained are correct.

[0154] Example 5: Detection and verification of the binding affinity of nanobodies to ATRN by ELISA

[0155] Use 0.2μg of enzyme-digested antibody in each well, add 100μL PBS, and keep in a 4°C refrigerator overnight. Wash the immunoplate three times with PBS, then add 300μL of MPBS (containing BSA to block nonspecific binding sites) to each well and block at room temperature for 3 hours. Wash the immunoplate three times with PBST, add 1000nM Fc-tagged antigen (dissolved in MPBS) starting from the starting well, then dilute ten-fold in each row, add 100μL to each well, and incubate at room temperature for one hour. Wash the immunoplate three times with PBST, then add HRP-coupled anti-IgG1 Fc antibody (Beijing Yiqiao Shenzhou) to detect nanobody-Fc fusion protein bound to the antigen, and incubate at room temperature for 1 hour. Wash the immunoplate five times with PBST, then add 100μLTMB (chromogenic substrate) to each well, incubate at room temperature in the dark for 10 minutes, then add 50μL 1M H2SO4 to each well to terminate the reaction. The results are as follows. Figure 6 As shown, with the increase of antigen concentration, the OD450 value gradually increased. When the antigen concentration was 1000nM, OD450 reached a maximum value of 1.081, indicating that the nanoantibody can specifically bind to the extracellular segment of ATRN with high affinity.

[0156] Example 6: Flow cytometry detection of the ability of nanobodies to stimulate human peripheral blood mononuclear cells (PBMC) to secrete cytokines

[0157] PBMCs were cultured in 96-well plates in 1640 medium supplemented with PHA (5 μg / ml), 1% double antibody and 10% FBS at 37°C and 5% CO2 for 96 h. The cell concentration was 2×10 6 / ml, the culture medium of the control group did not add PHA, and then the PBMC was blocked with PBS containing 10% mouse serum for 15 minutes, and then labeled with CD3-BV786 (Biolegend), CD8-PC7 (Biolegend), CD56-BV605 (Biolegend) flow cytometry antibodies, incubated in a 4°C refrigerator for 30 minutes, and then washed with PBS three times, and then the PBMC was fixed with a fixative for 1 hour (Invitrogen eBioscience), labeled with ATRN-AF647 flow cytometry antibodies (Santa Cruz) and its isotype control antibody (Biolegend), incubated in a 4°C refrigerator for 30 minutes, and washed three times with permeabilization buffer (Invitrogen eBioscience), and finally detected by flow cytometry. The results are shown in Figure 7 (A). Flowjo software analysis shows that compared with the control group, in PBMC stimulated with PHA for 96 hours, CD8 + T cells and NK cells highly express ATRN.

[0158] Anti-ATRN nanobody and FC protein were added to PBMC stimulated with PHA (5 μg / ml) for 96 h, and the antibody concentration was 200 nmol and cultured at 37°C, 5% CO2. PMA (30 ng / ml), ionomycin (1 μg / ml) and monensin (2.5 μg / ml) were added to stimulate PBMC for 4 hours at 48 h and 96 h of nanobody stimulation, respectively, and the cells were collected by centrifugation. The cells were blocked and labeled with external standard flow antibodies CD3-BV786 (Biolegend), CD8-PC7 (Biolegend), CD56-BV605 (Biolegend), permeabilized and fixed, labeled with internal standard flow antibodies IFN-γ-FITC (Biolegend), Perforin-BV421 (Biolegend), Granzyme B-ECD (Biolegend), TNF-α-APC (Biolegend), and their isotype control antibodies (Biolegend), and detected using a flow cytometer, and finally analyzed using flowjo software. The results are shown in Figure 7 (BC). Compared with the FC group, after 48 hours of co-incubation with anti-ATRN nanoantibodies, the ability of NK cells to secrete perforin was significantly enhanced, and after 96 hours of co-incubation with anti-ATRN nanoantibodies, the ability of CD8 + The ability of T cells to secrete interferon, tumor necrosis factor, and perforin.

[0159] Example 7: Anti-ATRN Nanobodies Inhibit HepG2 Subcutaneous Tumor Growth

[0160] In order to verify the therapeutic potential of the obtained nanobodies, 5×10 6 HepG2 cells were injected subcutaneously into NSG mice of appropriate age (6-8 weeks) to establish a tumor model. On the 12th day after injection, 5×10 6 PBMC, when the tumor volume reached at least about 100 cubic millimeters (15 days after tumor injection), the randomly divided mice were injected intraperitoneally with nanoantibodies, each dose containing about 200 μg of nanoantibodies (10 mg / kg), with an interval of 2-3 days between each dose, and each mouse was treated 5 times. In addition, the control group mice received an equal amount of PBS containing the drug solution. Within 24 days after the injection of tumor cells, the tumor growth was monitored every 2-3 days, and the volume was calculated according to the length × width 2 ×0.52 calculation, the result is as follows Figure 8 As shown in the figure, after the fifth treatment, the tumor growth of mice in the experimental group was significantly slowed down compared with that in the control group, indicating that anti-ATRN nanoantibodies have good therapeutic potential for HepG2 tumors.

[0161] The preferred embodiments of the present application are described in detail above, but the present application is not limited thereto. Within the technical concept of the present application, the technical solution of the present application can be subjected to a variety of simple modifications, including combining various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed in the present application and belong to the protection scope of the present application.

[0162] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present application. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0163] Although the embodiments of the present application have been shown and described above, it can be understood that the above embodiments are exemplary and cannot be understood as limitations on the present application. Ordinary technicians in this field can change, modify, replace and modify the above embodiments within the scope of the present application.

Claims

1. An antibody or an antigen-binding fragment thereof, characterized in that: include: A heavy chain complementarity determining region HCDR, wherein the HCDR comprises at least one selected from SEQ ID NO: 1 to 3 or an amino acid sequence having at least 80% homology thereto.

2. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The HCDR comprises: HCDR1, HCDR2 and HCDR3, wherein: The HCDR1 comprises an amino acid sequence as shown in SEQ ID NO: 1 or having at least 80% homology to SEQ ID NO: 1, The HCDR2 comprises an amino acid sequence as shown in SEQ ID NO: 2 or having at least 80% homology to SEQ ID NO: 2, and the HCDR3 comprises an amino acid sequence selected from the group consisting of an amino acid sequence as shown in SEQ ID NO: 3 or having at least 80% homology to SEQ ID NO: 3; Preferably, the HCDR comprises: HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NOs: 1 to 3, respectively.

3. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: Further including: The light chain complementarity determining region LCDR comprises LCDR1, LCDR2 and LCDR3.

4. The antibody or antigen-binding fragment thereof according to claim 2 or 3, characterized in that: The antibody or antigen-binding fragment thereof further comprises: a heavy chain framework region; Optionally, at least a portion of the heavy chain framework region is independently derived from at least one of an alpaca antibody, a shark antibody, a mouse antibody, a rabbit antibody, a primate antibody or a mutant thereof, preferably an alpaca antibody; Preferably, the heavy chain variable region of the antibody or antigen-binding fragment thereof comprises an amino acid sequence selected from SEQ ID NO: 4 or an amino acid sequence having at least 80% homology to SEQ ID NO: 4; preferably, the amino acid sequence of the heavy chain variable region of the antibody or antigen-binding fragment thereof is as shown in SEQ ID NO: 4; Optionally, the antibody or antigen-binding fragment thereof further comprises: a light chain framework region; Optionally, at least a portion of the light chain framework region is independently derived from at least one of a murine antibody, a rabbit antibody, a primate antibody or a mutant thereof.

5. The antibody or antigen-binding fragment thereof according to claim 4, characterized in that: The antibody or antigen-binding fragment thereof further comprises: a heavy chain constant region; Optionally, the antibody or antigen-binding fragment thereof further comprises: a light chain constant region; Optionally, at least a portion of the heavy chain constant region and the light chain constant region are independently derived from at least one of a rabbit antibody, a mouse antibody, a sheep antibody, a goat antibody, a primate antibody or a mutant thereof.

6. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The antibody comprises at least one selected from a polyclonal antibody and a monoclonal antibody; or The antigen-binding fragment comprises at least one selected from the group consisting of a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, a scFv fragment, a scFv-Fv fusion protein and a minimum recognition unit; Preferably, the antibody is a nanobody.

7. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6; Optionally, the nucleic acid molecule is DNA.

8. An expression vector, characterized in that Carrying the nucleic acid molecule according to claim 7.

9. A method for preparing the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, characterized in that: include: Introducing the expression vector of claim 8 into a cell; Cultivating the cells under conditions suitable for protein expression and secretion to obtain the antibody or antigen-binding fragment thereof; Optionally, the cell is a eukaryotic cell.

10. A recombinant cell, characterized in that The recombinant cell carries the nucleic acid molecule of claim 7 or the expression vector of claim 8.

11. A recombinant protein, characterized in that include: The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6; Optionally, further comprising at least one selected from a biologically active protein or a fragment thereof, a biologically active polypeptide or a fragment thereof; Optionally, the biologically active protein or fragment thereof comprises at least one selected from a protein tag, a protein toxin or a fragment thereof, a tumor necrosis factor or a fragment thereof, an interferon or a fragment thereof, a biological response regulator or a fragment thereof, and an Fc fragment.

12. A composition, characterized in that include: The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, carrying the nucleic acid molecule according to claim 7, the expression vector according to claim 8, the recombinant cell according to claim 10 or the recombinant protein according to claim 11.

13. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, the nucleic acid molecule according to claim 7, the expression vector according to claim 8, the recombinant cell according to claim 10, the recombinant protein according to claim 11 or the composition according to claim 12 in the preparation of a drug for treating or preventing ATRN-mediated related diseases.

14. The use according to claim 13, characterized in that The ATRN-mediated related diseases include neurological diseases, autism spectrum disorder (ASD), Alzheimer's disease, schizophrenia, Parkinson's disease, bipolar disorder, epilepsy, diabetic nephropathy, glomerulonephritis, chronic kidney disease, polycystic kidney disease, nephrotic syndrome, renal cell carcinoma, obesity, type II diabetes, non-alcoholic fatty liver disease, metabolic syndrome, hypothyroidism, Cushing's syndrome, hyperlipidemia, coronary artery disease, heart failure, stroke, peripheral artery disease, atrial fibrillation, atherosclerosis, hypertension, coronary artery disease, heart failure, arrhythmia, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, melanoma, breast cancer, lung cancer, colorectal cancer, prostate cancer, ovarian cancer, renal cell carcinoma, liver cancer, lung cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, thyroid cancer, skin cancer, prostate cancer, kidney cancer, endometrial cancer, cervical cancer and blood tumors.

15. A drug, characterized in that include: The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, the nucleic acid molecule according to claim 7, the expression vector according to claim 8, the recombinant cell according to claim 10, the recombinant protein according to claim 11 or the composition according to claim 12, wherein the drug is used to treat or prevent ATRN-mediated related diseases.

16. The drug according to claim 15, characterized in that The ATRN-mediated related diseases include neurological diseases, autism spectrum disorder (ASD), Alzheimer's disease, schizophrenia, Parkinson's disease, bipolar disorder, epilepsy, diabetic nephropathy, glomerulonephritis, chronic kidney disease, polycystic kidney disease, nephrotic syndrome, renal cell carcinoma, obesity, type II diabetes, non-alcoholic fatty liver disease, metabolic syndrome, hypothyroidism, Cushing's syndrome, hyperlipidemia, coronary artery disease, heart failure, stroke, peripheral artery disease, atrial fibrillation, atherosclerosis, hypertension, coronary artery disease, heart failure, arrhythmia, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, melanoma, breast cancer, lung cancer, colorectal cancer, prostate cancer, ovarian cancer, renal cell carcinoma, liver cancer, lung cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, thyroid cancer, skin cancer, prostate cancer, kidney cancer, endometrial cancer, cervical cancer and blood tumors; Optionally, the drug further comprises a pharmaceutically acceptable excipient; Optionally, the auxiliary materials include: one or more pharmaceutically acceptable excipients, diluents, stabilizers or carriers; Optionally, the drug is an injection.

17. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6 in the preparation of a kit for detecting ATRN.

18. A kit, characterized in that: The kit comprises: The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6.

19. The kit according to claim 18, characterized in that The kit is used for detecting ATRN.

Citation Information

Patent Citations

  • Application of plasma protein marker in EML4-ALK positive non-small cell lung cancer targeted therapy prognosis prediction

    CN116794312A

  • Nanometer antibody targeting Siglec-7 protein and application thereof

    CN118146371A

  • Novel polypeptide-human scretory type T cell activator protein and polynucleotide for encoding said polypeptide

    CN1345855A

  • Proteins and nucleic acids encoding same

    WO2002026826A2

Cited By

  • Gene mutant and application thereof

    CN121538223A

  • Antibody targeting ATRN protein or antigen-binding fragment thereof, and use thereof

    WO2026021622A3